Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/91059
DC FieldValueLanguage
dc.contributor.authorRaquel Boia-
dc.contributor.authorPaulo A.N. Dias-
dc.contributor.authorJoana M. Martins-
dc.contributor.authorCaridad Galindo-Romero-
dc.contributor.authorInês D. Aires-
dc.contributor.authorManuel Vidal-Sanz-
dc.contributor.authorMarta Agudo-Barriuso-
dc.contributor.authorHermínio C. de Sousa-
dc.contributor.authorAntónio Francisco Ambrósio-
dc.contributor.authorMara E.M. Braga-
dc.contributor.authorAna Raquel Santiago-
dc.date.accessioned2020-09-15T15:53:48Z-
dc.date.available2020-09-15T15:53:48Z-
dc.date.issued2019-11-09-
dc.identifier.issn01683659pt
dc.identifier.urihttp://hdl.handle.net/10316/91059-
dc.description.abstractThis work reports the development of porous poly (ε-caprolactone) (PCL)-based intraocular implants, prepared by green supercritical carbon dioxide (scCO2) foaming/mixing method (SFM), to produce implants that degrade faster than typical slow-degrading PCL-based implants. The higher porosities and surface areas of these implants led to faster degradation rates at in vitro accelerated alkaline conditions than low porosity/surface area implants prepared by hot melting processing. These porous implants also presented distinct (faster) release rates of a test-drug (dexamethasone). Additionally, these porous devices did not cause cell death and did not reduce the number of neurons, indicating that are not toxic to retinal cells. We further explored the impact of PCL-based implant to the retina by in vivo evaluation and histological analysis. Implants were surgically inserted in the vitreous of Wistar rats, and their presence did not change the function, structure and anatomy of the retina. These devices demonstrated a good intraocular tolerance, further confirming their viability for prolonged drug delivery applications. Further comprehensive studies based on this promising preliminary assessment and proof-of-concept could enable its future translation to clinical protective strategies for retinal diseases.pt
dc.description.sponsorshipThis work wasfinancially supported by FCT, Portugal (FellowshipsPD/BD/114115/2015, PD/BD/127821/2016, and SFRH/BPD/101048/2014, Grant PTDC/NEU-OSD/3123/2014 and Strategic Projects UID/NEU/04539/2013, PEst-C/EQB/UI0102/2013, PEst-C/EQB/UI0102/2018, and PEst-C/EQB/UI0102/2019), FEDER-COMPETE (FCOMP-01-0124-FEDER-028417 and POCI-01-0145-FEDER-007440) and Centro2020 Regional Operational Programme (CENTRO-01-0145-FEDER-000008: Brain Health 2020)pt
dc.language.isoengpt
dc.publisherElsevier {BV}pt
dc.relationFCT, Portugalpt
dc.relationFEDER-COMPETEpt
dc.relationCentro2020 Regional Operational Programmept
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt
dc.subjectBiodegradable porous implantspt
dc.subjectIntraocular drug deliverypt
dc.subjectPoly (ε-caprolactone)pt
dc.subjectRetinapt
dc.subjectSafetypt
dc.subjectSupercritical carbon dioxide foaming/mixing methodpt
dc.titlePorous poly(ε-caprolactone) implants: A novel strategy for efficient intraocular drug deliverypt
dc.typearticle-
degois.publication.firstPage331pt
degois.publication.lastPage348pt
degois.publication.locationThe Boulevard Langford Lane Kidlington Oxford OX5 1GB United Kingdompt
degois.publication.titleJournal of Contolled Releasept
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0168365919305632pt
dc.peerreviewedyespt
dc.identifier.doi10.1016/j.jconrel.2019.09.023pt
degois.publication.volume316pt
dc.date.embargo2019-11-09*
uc.date.periodoEmbargo0pt
item.languageiso639-1en-
item.fulltextCom Texto completo-
item.grantfulltextopen-
Appears in Collections:I&D IBILI - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
porous p.pdf4.33 MBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations 10

4
checked on Oct 22, 2020

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons